Introduction The biological pathways involved in the preclinical stage of the Alzheimer's
continuum are not well understood. Methods We used NeuroToolKit and Elecsys® …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Abstract Introduction The Alzheimer's Association convened a multidisciplinary workgroup to
develop appropriate use criteria to guide the safe and optimal use of the lumbar puncture …

Importance Different brain regions appear to be involved during β-amyloid (Aβ)
accumulation in Alzheimer disease (AD), but a longitudinally valid system to track Aβ stages …

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

Background: Decreased concentrations of amyloid-ß 1-42 (Aß42) in cerebrospinal fluid
(CSF) and increased retention of Aß tracers in the brain on positron emission tomography …

Introduction This study examines the utility of a multipanel of cerebrospinal fluid (CSF)
biomarkers complementing Alzheimer's disease (AD) biomarkers in a clinical research …

Background and Objectives To determine how fully automated Elecsys CSF immunoassays
for β-amyloid (Aβ) and tau biomarkers and an ultrasensitive Simoa assay for neurofilament …

Objective: To determine the relationship between sleep quality and CSF markers of
Alzheimer disease (AD) pathology in late midlife. Methods: We investigated the relationship …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …